Susquehanna International Group, LLP Rubius Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $171,275 - $419,120	40,300 Added 126.33%	72,200 $398,000
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $151,976 - $278,518	15,700 Added 96.91%	31,900 $309,000
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $3.9 Million - $5.75 Million	-221,800 Reduced 93.19%	16,200 $290,000
Q2 2021 Aug 11, 2021	BUY	$22.26 - $28.43 $1.16 Million - $1.49 Million	52,300 Added 28.16%	238,000 $5.81 Million
Q1 2021 May 17, 2021	BUY	$8.02 - $32.01 $1.49 Million - $5.94 Million	185,700 New	185,700 $4.92 Million
Q4 2019 Feb 14, 2020	SELL	$7.23 - $14.12 $697,695 - $1.36 Million	-96,500 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$7.85 - $15.75 $757,525 - $1.52 Million	96,500 New	96,500 $758,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.